期刊文献+

组织速度成像对蒽环类药物心脏毒性的评价 被引量:4

Evaluation of Anthracycline Antineoplastic Drugs Induced Myocardial Damage by Using Quantitative Tissue Velocity Imaging
原文传递
导出
摘要 目的探讨利用组织多普勒定量组织速度成像QTVI技术对蒽环类药物早期心脏毒性进行评估。方法 30例在江北人民医院化疗的肿瘤患者,所用化疗方案以表阿霉素(Epi)为主,表阿霉素总累计量(450±75)mg/m2,每个疗程治疗前进行组织多普勒定量组织速度成像和常规超声心动图检查。同时设健康对照组20例。常规超声心动图指标包括左室舒张末内径(LVDd),左室收缩末内径(LVDs),左室射血分数(LVEF),室间隔与左室后壁厚度(IVSTd、LVP-WTd),二尖瓣口血流速度(早期速度E、晚期速度A及两者比值E/A);定量组织速度成像测量二尖瓣环上左室侧壁及后间隔两个位点的峰值速度(收缩期峰值Vs、收缩期加速度a,舒张期峰值Ve)。结果与第一次治疗前对比,常规超声指标LVDd、LVDsI、VSTd、LVPWTd差别无统计学意义(P>0.05),左室射血分数在累积量达到450 mg/m2时差别有统计学意义(50.1±7.3与68.0±9.0,P<0.05)。舒张期指标E/A在累积量达到375 mg/m2时差别有统计学意义(0.71±0.14与1.20±0.21,P<0.05)。利用组织多普勒QTVI技术检测对比发现,收缩期指标Vs、a在累积量达300 mg/m2时差别有统计学意义([5.70±1.07)cm/s与(7.84±1.10)cm/s(、132±14)cm/s2与(219±31)cm/s2,P<0.05],舒张期指标Ve在累积量达到225 mg/m2差别有统计学意义([6.86±1.04)cm/s与(8.74±1.32)cm/s,P<0.05]。结论在监测表阿霉素心脏毒性上,组织多普勒超声心动图较常规超声心动图能较早期和较敏感发现心脏损害,且舒张功能的损害早于收缩功能。 Objective To evaluate the early cardiac toxicity cased by anthracycline antineoplastic drugs by using quantitative tissue velocity imaging(QTVI). Methods Thirty tumor patients and 20 normal controls were enrolled in this study. The chemotherapy drugs was mainly with a total dose of ( 450 ± 75 ) mg/m^2 epirubicin. The conventional eehoeardiography and tissue Doppler echoeardiography QTVI parameters were measured before every treatment courses. The conventional eehoeardiography pa- rameters included left ventricular end-diastolic diameter(LVDd) ,left ventricular end-systolic diameter(LVDs) ,intermediate ven- tricttlar septal thickness ( IVSTd ), left ventricular posterior wall diameter( LVPWd ), left ventrieular ejection fraction ( LVEF), early and late wave of mitral valve flow(E/A) ;The tissue Doppler echoeardiography parameters included peak velocity during systole (Vs) systolic acceleration(a) and peak diastolic velocity(Ve). Results Compared to baseline before the first period, there was no significant change in conventional echocardiography systolic parameters LVEDD, LVESD, IVST, LVPWd ( P 〉 0.05 ) ; LVEF changed significantly at total dose of 450 mg/m2 ( 50.1 ± 7.3 and 68.0 ±9.0, P 〈 0.05 ) ; the conventional eehoeardiography di- astolic parameter E/A changed significantly at total dose of 375 rag/m2 (0.71 ±0.14 and 1.20 ± 0.21,P 〈 0.05 ) ;While tissue Doppler eehocardiography QTVI parameters peak velocity during systole(Vs) and systolic acceleration (a) changed significantly at total of dose 300 mg/m2[(5.70±1.07) cm/s and (7.84±1.10) cm/s,(132±14) cm/s2 and (219 ±31) cm/s2,P〈 0.05] ,tissue Doppler eehoeardiography diastolic parameter peak diastolic veloeity(Ve) changed significantly at total of dose 225 mg/m2 [ (6.86 ± 1.04) cm/s and (8.74 ± 1.32) cm/s,P 〈 0.05 ]. Conclusion Tissue Doppler provides a new sensitive and early method to evaluate LV function in monitoring epirubiein cardiac toxicity as compared to the conventional eehoeardiography, and diastolic parameter alters earlier than systolic parameter.
作者 张颖 嵇平
出处 《中华全科医学》 2011年第1期10-11,共2页 Chinese Journal of General Practice
基金 江苏省南京市医学科技发展项目(YKK10185)
关键词 蒽环类化疗药物 心脏毒性 超声心动图 定量组织速度成像 Anthracycline antineoplastie drugs Cardiac toxicity Echoeardiogram Quantitative tissue velocity imaging
  • 相关文献

参考文献10

  • 1郑玮,李安华.超声心动图在抗肿瘤药物心脏毒性评价领域的进展[J].中国医学影像技术,2009,25(1):156-158. 被引量:2
  • 2Kremer LC, Vam-Dalen EC, Offringa M, et al. Anthracycaline induced clinical heart failure-up study [ J ]. J Clin Oncol, 2001 , 19 ( 1 ) : 191- 196.
  • 3Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxombicin: a retrospective analysis of three trials [ J ]. Cancer,2003,97( 11 ) :2869-2879.
  • 4Villani F, Meazza R, Materazzo C. Non-invasive monitoring of cardiac hcmodynamic parameters in doxorubiein treated patients: comparison with echocardiography [ J ]. Anticancer Res ,2006,26 ( 1 B) :797-801.
  • 5Elbl L, Vasova 1, Kral Z,et al. Eehoeardiographic evaluation of early and chronic eardiotoxieity in adult patients treated for Hodgkin. s disease with ABVD regimen[ J]. Neoplasma,2006,53 ( 1 ) :62-66.
  • 6礼广森,任卫东,张卓,崔洪岩,夏稻子,马春燕.组织追踪法评价阿霉素致兔心脏毒性左心室收缩功能影响的研究[J].中国医学影像技术,2007,23(3):346-348. 被引量:5
  • 7Sanderson JE,Wang M,Yu CM. Tissue Doppler imaging for predicting outcome in patients with cardiovascular disease[ J]. Curr Opin Cardio, 2004,19 ( 5 ) :458-463.
  • 8Dokainish H. Tissue Doppler imaging in the evaluation of left ventrieular diastolic function [ J ]. Curr Opin Cardio,2004,19 ( 5 ) :437-441.
  • 9Tassan-Mangina S,Codorean D, Metivier M,et al. Tissue Doppler imaging and conventionalcchocardiugraphy after anthracycline treatment in aduhs:early and late alterations of left ventricular function during a prospective study[ J ]. Eur J Echocardiogr,2006,7 ( 2 ) : 141-146.
  • 10杨好意,邓又斌,常青,毕小军,向慧娟,潘敏,黎春蕾.定量组织速度成像和组织追踪法对扩张型心肌病患者左心室收缩功能的研究[J].中华超声影像学杂志,2003,12(4):203-206. 被引量:31

二级参考文献24

共引文献35

同被引文献60

  • 1Oliveira PJ, Santos MS, Wallace KB. Doxorubicin-inducedthiol-dependent alteration of cardiac mitochondrial permeability transition and respiration [ J ]. Biochem ( Mose ),2006,71 ( 2 ) : 194-199.
  • 2Ramirez J,Duffort D, Obispo TM, et al. Group 5 determination in Pooideae grass pollen extracts by monoclonal antibody-based ELISA. Correlation with biologic activity[J]. Allergy, 1997, 52 (8) : 806-813.
  • 3Ramirez-Ramirez MA, Sobrino-Cossio S, de laMora-Levy JG, et al. Loss of expression of DNA mismatch repair proteins in aberrant crypt foci identified in vivo by magnifying colonoscopy in. subjects with hereditary nonpolyposic and sporadic colon rectal cancer. J Gastrointest Cancer,2012,12(2) :209-214.
  • 4Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of antican- cer drugs :!he need for eardio-oncology and cardiooncologieal pre- vention. J Natl Cancer Inst,2010,102( 1 ) : 14-25.
  • 5Lipshultz SE,Scully RE, Lipsitz SR, et al. Assessment of dexrazox- aneas a cardioprotectant in doxombicin-treated children with high- risk acute lymphoblastic leukacmia: long-term follow-up of a pro- spective, randomised, multicentre trial. Lancet Oncol, 2010, 11 (10) :950-961.
  • 6Blowers E, Hall K. Managing adverse event s in the use of bevaci- zumab and chemotherapy. Nurs,2009,18 (6) : 351-356.
  • 7Meyersohn NM, Pursnani A, Neilan TG. Detection of cardiac toxicity due to cancer treatment:role of cardiac MRI[ J]. Curr Treat Options Cardiovasc Med, 2015,17(8) :396-401.
  • 8Zheng R, Zeng H, Zhang S, et al. National estimates of cancer prevalence in Chi- na,2011 [J]. Cancer Lett,2016,370( 1 ) :33-38.
  • 9Chen J, Long JB, Hurria A, et al. Incidence of heart failure or cardiomyopathy af- ter adjuvant trastuzumab therapy for breast cancer[ J]. J Am Coll Cardio1,2012, 60(24) :2504-2512.
  • 10Goldhar HA, Yan AT, Ko DT,et al. The Temporal Risk of Heart Failure Associ- ated With Adjuvant Trastuzumab in Breast Cancer Patients:A Population Study [J].J Nail Cancer Iust,2015,108(1). pii:djv301.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部